Exodus Point Capital Management, LP Protagonist Therapeutics, Inc Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$16.68 - $23.66 $2.71 Million - $3.84 Million	162,471 Added 1108.71%	177,125 $2.95 Million
Q2 2023 Aug 10, 2023	BUY	$18.02 - $29.36 $264,065 - $430,241	14,654 New	14,654 $405,000
Q4 2022 Feb 13, 2023	SELL	$7.36 - $11.17 $138,139 - $209,649	-18,769 Reduced 17.24%	90,107 $983,000
Q3 2022 Nov 10, 2022	SELL	$7.86 - $11.71 $17,685 - $26,347	-2,250 Reduced 2.02%	108,876 $918,000
Q2 2022 Aug 19, 2022	BUY	$7.06 - $25.52 $784,549 - $2.84 Million	111,126 New	111,126 $879,000
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $298,633 - $489,086	-15,701 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $290,311 - $394,566	15,701 New	15,701 $317,000
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $270,468 - $390,342	-30,119 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $103,473 - $219,204	15,919 Added 112.11%	30,119 $379,000
Q4 2018 Feb 14, 2019	BUY	$6.3 - $10.44 $89,460 - $148,248	14,200 New	14,200 $96,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.92B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.